We are live on ! Find out more
CAC

Cowen and Company Portfolio holdings

AUM $2.97B
1-Year Est. Return 105.26%
This Fund
S&P 500
This Quarter Est. Return
-0.31%
1 Year Est. Return
+105.26%
3 Year Est. Return
+120.06%
5 Year Est. Return
+670.57%
10 Year Est. Return
AUM
$1.1B
AUM Growth
-$1.01B
Cap. Flow
-$635M
Cap. Flow %
-57.59%
Top 10 Hldgs %
36.04%
Holding
915
New
342
Increased
119
Reduced
101
Closed
282

Sector Composition

Rank Sector Weight
1 Financials 27.17%
2 Healthcare 26.29%
3 Technology 9.65%
4 Industrials 7.84%
5 Consumer Discretionary 3.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IPOF
1
DELISTED
Social Capital Hedosophia Holdings Corp. VI
IPOF
$66.7M 6.05%
6,549,093
+6,337,847
+3,000% +$65.1M
ESTA icon
2
Establishment Labs
ESTA
$2.71B
$54.8M 4.97%
810,687
+187,000
+30% +$13.1M
FTAI icon
3
FTAI Aviation
FTAI
$20.2B
$54.6M 4.95%
2,211,715
+368,665
+20% +$8.06M
SMFG icon
4
Sumitomo Mitsui Financial
SMFG
$159B
$40.6M 3.68%
5,976,605
CTLP
5
DELISTED
Cantaloupe
CTLP
$34.7M 3.14%
3,903,464
+1,330,476
+52% +$13.2M
CCVI
6
DELISTED
Churchill Capital Corp VI
CCVI
$34.2M 3.1%
+3,494,970
New +$34.4M
AVDL
7
DELISTED
Avadel Pharmaceuticals
AVDL
$30.2M 2.74%
3,732,778
+1,207,326
+48% +$11M
PEGR
8
DELISTED
Project Energy Reimagined Acquisition Corp. Class A Ordinary Share
PEGR
$29.7M 2.69%
+3,000,000
New +$29.1M
AMD icon
9
Advanced Micro Devices
AMD
$700B
$27.5M 2.49%
191,007
+167,861
+725% +$22.6M
APYX icon
10
Apyx Medical
APYX
$162M
$24.4M 2.21%
1,902,003
+23,000
+1% +$322K
ARKK icon
11
ARK Innovation ETF
ARKK
$5.59B
$23.6M 2.14%
+250,000
New +$27.3M
RCKT icon
12
Rocket Pharmaceuticals
RCKT
$343M
$21.8M 1.98%
1,000,000
INVZ icon
13
Innoviz Technologies
INVZ
$84.1M
$20.6M 1.87%
3,249,862
+2,324,844
+251% +$13.3M
ET icon
14
Energy Transfer Partners
ET
$69.5B
$18.4M 1.67%
+2,236,536
New +$20.3M
CLDX icon
15
Celldex Therapeutics
CLDX
$2.94B
$18M 1.64%
466,591
-182,687
-28% -$7.96M
XGN icon
16
Exagen
XGN
$105M
$16.1M 1.46%
1,384,631
HCVIU
17
DELISTED
Hennessy Capital Investment Corp. VI Unit
HCVIU
$15M 1.36%
1,500,000
-5,953
-0.4% -$59.4K
PRQR icon
18
ProQR Therapeutics
PRQR
$244M
$12.5M 1.14%
1,564,844
+1,298,183
+487% +$9.89M
TARS icon
19
Tarsus Pharmaceuticals
TARS
$2.55B
$11.6M 1.05%
514,289
VMW
20
DELISTED
VMware, Inc
VMW
$11.4M 1.03%
98,300
-1,932
-2% -$254K
BWAY
21
Brainsway
BWAY
$568M
$10.8M 0.98%
2,794,818
SNCE
22
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$9.86M 0.89%
39,533
+2,915
+8% +$647K
ADER
23
DELISTED
26 Capital Acquisition Corp
ADER
$9.85M 0.89%
+1,000,000
New +$9.85M
ARKK icon
24
PUT
ARK Innovation ETF
ARKK
$5.59B
$9.8M 0.89%
+265,000
New +$28.9M
BHP icon
25
BHP
BHP
$211B
$9.35M 0.85%
173,755

Similar funds

Cowen and Company's Q4 2021 Portfolio in Review

As of Q4 2021, Cowen and Company held 915 positions worth $1.1B, down 48% from $2.11B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Cowen and Company withdrew a net $635M in Q4 2021, closing 282 positions and reducing 101 holdings. Its most notable exit was iShares iBoxx $ High Yield Corporate Bond ETF, an estimated $268M position sold in full.

By sector, the portfolio is most concentrated in Financials at 27% of assets, up from 5.5% a quarter earlier, followed by Healthcare and Technology.

Against the trend, Cowen and Company opened a new position in Churchill Capital Corp VI worth $34.2M.

  • Cowen and Company's largest Q4 2021 buy was Churchill Capital Corp VI: 3,494,970 shares worth $34.2M.
  • Cowen and Company added most to Social Capital Hedosophia Holdings Corp. VI in Q4 2021, an estimated $65.1M increase.
  • Cowen and Company's biggest Q4 2021 reduction was Invesco QQQ Trust, cutting an estimated $146M.
  • Cowen and Company fully exited iShares iBoxx $ High Yield Corporate Bond ETF in Q4 2021, selling an estimated $268M.
  • Cowen and Company's ten largest holdings make up 36% of its $1.1B portfolio in Q4 2021.
  • Cowen and Company opened 342 new positions and closed 282 in Q4 2021.
  • Cowen and Company's portfolio value fell 48% quarter-over-quarter to $1.1B.

Based on Cowen and Company's 13F filing for Q4 2021, filed 14 Feb 2022.